Khavinson bioregulators — Pinealon, Cortexin, and the short-peptide theory

The Khavinson bioregulator framework is one of the more interesting theoretical constructs in peptide biology. The empirical support outside his own institute is limited. Epithalon got the most external attention because it had a clear mechanistic story (telomerase). The others — Pinealon, Cortexin, etc — are mostly supported by Khavinson-group trials.

Cortexin is used clinically in Russia for cognitive rehab post-stroke. It's a polypeptide extract, not a single molecule, which puts it in the same 'what even is this' bucket as Cerebrolysin. Less characterized than Epithalon by a lot.

The short peptide bioregulator theory — that short sequences have tissue-specific regulatory effects via direct DNA interaction — is an interesting idea with mostly Khavinson-sourced support. External mechanistic replication is thin. File under 'interesting, unproven.'

Ran Pinealon for one 10-day cycle alongside Epi. Subjectively couldn't tell it apart from Epi alone. Dropped it.

@epi_cycler that's useful. If Pinealon added nothing on top of Epi, it's either redundant at the pineal level or the 'tissue specificity' framing is looser than advertised.

The whole bioregulator family is where my skepticism meter runs hottest. Not because the theory is bad — it's actually elegant — but because the evidence base is essentially one lab, one country, over decades.

Cortexin as the 'Cerebrolysin lite' framing isn't totally crazy. Both are porcine-ish brain-derived peptide mixtures with overlapping use cases. Different preparation, different regulatory histories.

If someone's going to run a Khavinson bioregulator beyond Epithalon, start with the specific tissue-related outcome you're trying to move and work backwards. Don't run Cortexin 'for brain health' generally — run it for a specific cognitive complaint, with a measurement, and a stop date.